Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | CALCR | P30988 | 4/20 | 0.58 |
| ▸ | NPY2R | P49146 | 7/20 | 0.58 |
| ▸ | NPY4R | P50391 | 7/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.58 |
| ▸ | NPY1R | P25929 | 5/20 | 0.58 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148163 | 1.00 | C5AR1 (0.62) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29637925 | 0.99 | C5AR1 (0.63) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30523596 | 0.98 | C5AR1 (0.62) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31386975 | 0.96 | CALCR (0.63) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30523581 | 0.95 | CALCR (0.63) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29637944 | 0.95 | C5AR1 (0.65) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31386983 | 0.94 | C5AR1 (0.58) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30432183 | 0.91 | F2 (0.59) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30436896 | 0.90 | CALCR (0.68) | C5AR1CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29695646 | 0.89 | NPY2R (0.63) | C5AR1CALCRNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022148781-A1 | COMBINATION OF MCOLN ACTIVATORS AND IMMUNE CHECKPOINT INHIBITORS | INSTITUT CURIE (FR) | 2022-07-14 | — | — | WO | claimed |
| WO-2026104809-A1 | THERAPEUTIC BACTERIAL COMPOSITIONS | Microbiotica Limited (GB) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104810-A1 | ISOLATED BACTERIA OR CULTURE SUPERNATANTS THEREOF FOR THE TREATMENT OF CANCER | Microbiotica Limited (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-20230346850-A1 | Therapeutic Bacterial Composition | MICROBIOTICA LTD (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230183297-A1 | METHODS OF TREATMENT AND RELATED COMPOSITIONS | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2023-06-15 | — | — | US | disclosed |
| EP-4153786-A1 | THERAPEUTIC BACTERIAL COMPOSITION | Microbiotica Limited (GB) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153787-A1 | BACTERIAL BIOMARKER | Microbiotica Limited (GB) | 2023-03-29 | — | — | EP | disclosed |
| US-20230090495-A1 | Bacterial Biomarker | MICROBIOTICA LTD (GB) | 2023-03-23 | — | — | US | disclosed |
| US-11505579-B2 | Methods of treatment and related compositions | ASCEND BIOPHARMACEUTICALS, INC. (AU) | 2022-11-22 | — | — | US | disclosed |
| US-11439671-B2 | Therapeutic bacterial composition | Microbiotica Limited (GB) | 2022-09-13 | — | — | US | disclosed |
| US-20220235097-A1 | METHODS OF TREATMENT AND RELATED COMPOSITIONS | ASCEND BIOPHARMACEUTICALS LTD (AU) | 2022-07-28 | — | — | US | disclosed |
| WO-2022148781-A1 | COMBINATION OF MCOLN ACTIVATORS AND IMMUNE CHECKPOINT INHIBITORS | INSTITUT CURIE (FR) | 2022-07-14 | — | — | WO | disclosed |
| US-11376285-B2 | Bacterial biomarker | Microbiotica Limited (GB) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505579-B2 | Methods of treatment and related compositions | SMO, SHH, GLI1 | C5AR1 843/4885CALCR 2108/4885NPY2R 2179/4885 |
| US-20230183297-A1 | METHODS OF TREATMENT AND RELATED COMPOSITIONS | SMO, SHH, GLI1 | C5AR1 843/4885CALCR 2108/4885NPY2R 2179/4885 |
| US-20220235097-A1 | METHODS OF TREATMENT AND RELATED COMPOSITIONS | SMO, SHH, GLI1 | C5AR1 843/4885CALCR 2108/4885NPY2R 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.